Alan J. Dalby

Health Technology

Consumer Non-Durables

Profile

Alan Dalby became a Non-executive Director of Acambis on 1 May 1998.
He was an executive director of SmithKline, a predecessor company to GlaxoSmithKline plc, and retired from the role of Chairman of Reckitt Benckiser plc in 2001.
He is a director of Alteon, Inc., a US-based biotechnology company.
He is the senior independent Non-executive Director.
The Board considers Mr Dalby to be an independent Non-executive Director.
He is a member of the Audit Committee and Nominations Committee, and Chairman of the Remuneration Committee.

Former positions of Alan J. Dalby

Companies	Position	End
Acambis Plc Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK.	Director/Board Member	22/09/2008
RECKITT BENCKISER GROUP PLC	Chairman	01/01/2001
Smithkline Beecham Plc Smithkline Beecham Plc Pharmaceuticals: OtherHealth Technology Smithkline Beecham Plc develops and manufactures pharmaceutical products. The company markets pharmaceuticals for human and animal healthcare consumption, vaccines, over the counter medicines, health related consumer products, clinical laboratory testing services, disease management and pharmaceutical benefit management. It is headquartered in Brentford, UK.	Director/Board Member	-
SYNVISTA THERAPEUTICS, INC.	Director/Board Member	-

See the detail of Alan J. Dalby's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies